Gene therapy with viral vectors
NA Kootstra, IM Verma - Annual review of pharmacology and …, 2003 - annualreviews.org
A key factor in the success of gene therapy is the development of gene delivery systems that
are capable of efficient gene transfer in a broad variety of tissues, without causing any …
are capable of efficient gene transfer in a broad variety of tissues, without causing any …
[HTML][HTML] The role of macrophages in HIV-1 persistence and pathogenesis
Z Kruize, NA Kootstra - Frontiers in microbiology, 2019 - frontiersin.org
Current antiretroviral therapy (ART) effectively suppresses Human Immunodeficiency Virus
type 1 (HIV-1) in infected individuals. However, even long term ART does not eradicate HIV-1 …
type 1 (HIV-1) in infected individuals. However, even long term ART does not eradicate HIV-1 …
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from …
H Schuitemaker, M Koot, NA Kootstra… - Journal of …, 1992 - Am Soc Microbiol
The composition of human immunodeficiency virus type 1 (HIV-1) clonal populations at different
stages of infection and in different compartments was analyzed. Biological HIV-1 clones …
stages of infection and in different compartments was analyzed. Biological HIV-1 clones …
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
…, K Sliepen, A Aartse, R Derking, I Bontjer, NA Kootstra… - Science, 2020 - science.org
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
had a large impact on global health, travel, and economy. Therefore, preventative and …
had a large impact on global health, travel, and economy. Therefore, preventative and …
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule
RA Fouchier, M Groenink, NA Kootstra… - Journal of …, 1992 - Am Soc Microbiol
The third variable (V3) domain has been implicated in determining the human immunodeficiency
virus (HIV) phenotype, including fusion capacity and monocytotropism. In a large set of …
virus (HIV) phenotype, including fusion capacity and monocytotropism. In a large set of …
Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEh …
…, FW Wit, IG Stolte, NA Kootstra… - Clinical Infectious …, 2014 - academic.oup.com
Age-associated comorbidities (cardiovascular and renal disease) were more prevalent
among HIV-positive compared with HIV-uninfected patients. Comorbidity was associated with …
among HIV-positive compared with HIV-uninfected patients. Comorbidity was associated with …
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission.
AB Van't Wout, NA Kootstra… - The Journal of …, 1994 - Am Soc Clin Investig
Macrophage-tropic, non-syncytium-inducing, HIV-1 variants predominate in the asymptomatic
phase of infection and may be responsible for establishing infection in an individual …
phase of infection and may be responsible for establishing infection in an individual …
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity
…, S Toivonen, CAM Koeleman, S Sainio, NA Kootstra… - Science, 2021 - science.org
INTRODUCTION Antibody function is often considered static and mostly determined by
isotype and subclass. The conserved N-linked glycan at position 297 in the Fc domain of …
isotype and subclass. The conserved N-linked glycan at position 297 in the Fc domain of …
Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences
…, V Cobos Jiménez, NA Kootstra… - Blood, The Journal …, 2013 - ashpublications.org
The molecular repertoire of macrophages in health and disease can provide novel biomarkers
for diagnosis, prognosis, and treatment. Th2-IL-4–activated macrophages (M2) have …
for diagnosis, prognosis, and treatment. Th2-IL-4–activated macrophages (M2) have …
Immunogenicity and reactogenicity of vaccine boosters after Ad26. COV2. S priming
…, VASH Dalm, NA Kootstra… - … England Journal of …, 2022 - Mass Medical Soc
Background The Ad26.COV2.S vaccine, which was approved as a single-shot immunization
regimen, has been shown to be effective against severe coronavirus disease 2019. …
regimen, has been shown to be effective against severe coronavirus disease 2019. …
